STOCK TITAN

Aligos Therapeutics, Inc. - ALGS STOCK NEWS

Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical-stage biopharmaceutical company advancing novel therapies for chronic hepatitis B (CHB) and metabolic dysfunction-associated steatohepatitis (MASH). This page aggregates official press releases and verified news about the company’s clinical developments, research breakthroughs, and strategic partnerships.

Investors and industry professionals will find timely updates on ALGS’ pipeline candidates including oral capsid assembly modulators targeting viral suppression in CHB and THR-β agonists addressing liver fat reduction in MASH. The curated news collection provides essential context for understanding clinical trial progress, regulatory milestones, and scientific advancements.

Key content categories include updates on: Phase 1-3 clinical trials, collaborative research initiatives, regulatory communications, and therapeutic mechanism insights. All information is sourced from official company disclosures and reputable industry publications.

Bookmark this page for structured access to ALGS’ evolving scientific narrative. Check regularly for developments in oligonucleotide-based therapies and small molecule candidates progressing through clinical evaluation.

Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS) has announced a 1-for-25 reverse stock split effective August 19, 2024. The company's common stock will continue trading on the Nasdaq Capital Market under the same symbol with a new CUSIP number. This move primarily aims to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The reverse split will affect all outstanding stock options, warrants, and equity incentive plans proportionally. No fractional shares will be issued, with stockholders receiving cash payments instead. The split was approved by stockholders on June 27, 2024, and subsequently by the Board of Directors. Continental Stock Transfer & Trust Company is acting as the exchange and transfer agent for the process.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.64%
Tags
-
Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS) has appointed two new independent directors to its Board: Dr. Heather Preston and Margarita Chavez, J.D. Dr. Preston, with over 30 years of healthcare industry experience, will chair the Nominating and Corporate Governance Committee. Ms. Chavez, bringing 25 years of dealmaking expertise, will join the Audit Committee. Both appointments are effective August 7, 2024.

Dr. Preston, currently a Senior Advisor to TPG Biotech, has a background in investing and medical practice. Ms. Chavez, a Venture Partner at Wellington Partners, has extensive experience in biopharmaceutical dealmaking. These appointments aim to strengthen Aligos's Board as the company progresses its drug candidates for liver and viral diseases through clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
none
-
Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS) reported Q2 2024 financial results and business progress. Key highlights include:

1. Completed enrollment for Phase 2a HERALD study of ALG-055009 (THR-β agonist for MASH), with topline data expected in early Q4 2024.

2. Presented promising data for ALG-000184 (CAM-E for CHB) at EASL Congress 2024, showing sustained HBV DNA suppression.

3. Received positive FDA feedback for ALG-000184, supporting future studies with sustained HBV DNA suppression as the primary endpoint.

4. Q2 2024 net income of $5.1 million ($0.03 per share), primarily due to a decrease in warrant liability.

5. Cash balance of $94.5 million as of June 30, 2024, expected to fund operations through end of 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.92%
Tags
Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral diseases, has announced that it will release its second quarter 2024 financial results on Tuesday, August 6, 2024. The report will be made available after the close of U.S. financial markets. This announcement is significant for investors and analysts who closely follow the company's financial performance and progress in developing novel therapeutics for unmet medical needs in liver and viral diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS) has announced a clinical trial collaboration with Xiamen Amoytop Biotech to evaluate the combination of ALG-000184 and PEGBING® (Mipeginterferon alfa-2b) in chronic hepatitis B (CHB) patients in China. Amoytop will sponsor a Phase 1b exploratory study to assess the efficacy and safety of this combination.

ALG-000184 is a potent oral capsid assembly modulator (CAM-E) designed to disrupt hepatitis B cccDNA levels and reduce viral markers. It has shown promising results in Phase 1a and 1b studies. PEGBING®, developed by Amoytop, is a 40kD pegylated interferon α-2b injection used in viral hepatitis treatment.

The 48-week Phase 1b study will compare ALG-000184 + PEGBING® + entecavir (ETV) with ALG-000184 + ETV or PEGBING® + ETV in HBeAg-positive and HBeAg-negative CHB subjects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
none
-
Rhea-AI Summary

Aligos Therapeutics announced a virtual KOL event on July 18, 2024, featuring Dr. Mark Sulkowski to discuss positive Phase 1b data for ALG-000184 in treating chronic hepatitis B (CHB). The event will cover the unmet needs in CHB treatment, current landscape, and future development plans following positive FDA feedback. Aligos' CEO, Lawrence Blatt, highlighted the promising results of ALG-000184 monotherapy, showing significant viral suppression without breakthrough, and its superior efficacy compared to existing treatments. The KOL event aims to provide further insights into the regulatory pathway for chronic suppression.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.82%
Tags
conferences clinical trial
Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS) announced positive data at the EASL Congress 2024, highlighting the antiviral efficacy of ALG-000184 for chronic hepatitis B (CHB). The data showed that 90% of HBeAg-positive patients had sustained HBV DNA suppression after 72 weeks of 300 mg daily oral monotherapy. In HBeAg-negative patients, 100% achieved complete suppression of HBV DNA and RNA after 60 weeks, with no viral breakthroughs reported. The treatment was well tolerated and showed a positive trend in anti-HBe antibody levels. Additionally, preclinical data demonstrated the potential of next-generation siRNAs for metabolic dysfunction-associated steatohepatitis (MASH) and CHB, as well as a novel CAM-A molecule for CHB treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS), a clinical-stage biopharmaceutical company, announced that six of its abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2024, taking place from June 5-8 in Milan, Italy. The accepted abstracts include findings on their novel therapeutics for liver and viral diseases.

Highlighted abstracts involve the Capsid Assembly Modulator (CAM) ALG-000184, which has shown promising antiviral effects in chronic hepatitis B (CHB) patients. Notably, two abstracts have earned 'Top' recognition for their outstanding contribution: one on second-generation HBV siRNAs demonstrating improved profiles, and another on CAM-A molecules inducing rapid HBsAg reductions in animal models.

The presentations cover both preclinical and clinical research, reflecting Aligos' leadership in addressing unmet medical needs in liver diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.95%
Tags
none
-
Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS) has completed enrollment for its Phase 2a HERALD study of ALG-055009, targeting metabolic dysfunction-associated steatohepatitis (MASH). The study enrolled around 100 subjects with liver fibrosis. Topline safety and efficacy data are expected in early Q4 2024.

Dr. Rohit Loomba, a renowned expert in gastroenterology and hepatology, will serve as the Principal Investigator. The trial involves a double-blind, placebo-controlled design with subjects receiving one of four doses or placebo for 12 weeks. The primary endpoint is the relative change in liver fat content measured by MRI-PDFF.

The study aims to assess safety, pharmacokinetics, and other non-invasive biomarkers influenced by thyroid hormone receptor beta agonists. The completion of enrollment is a significant milestone for Aligos.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.77%
Tags
Rhea-AI Summary

Aligos Therapeutics, a clinical stage biopharmaceutical company, reported recent business progress and financial results for the first quarter of 2024. They initiated the Phase 2a HERALD study of their drug candidate ALG-055009 and presented positive data on their other programs at scientific conferences. The company's cash balance remains strong to fund operations until the end of 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
Aligos Therapeutics, Inc.

Nasdaq:ALGS

ALGS Rankings

ALGS Stock Data

28.61M
4.70M
11.58%
34.03%
20.13%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO